GC
VNDA icon

Globeflex Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Globeflex Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-96,331
Closed -$416K – 511
2023
Q3 		$416K Sell
96,331
-1,836
-2% -$10.2K 0.05% 261
2023
Q2 		$647K Sell
98,167
-2,676
-3% -$17.2K 0.07% 222
2023
Q1 		$685K Hold
100,843
– – 0.08% 222
2022
Q4 		$745K Hold
100,843
– – 0.09% 213
2022
Q3 		$996K Hold
100,843
– – 0.17% 171
2022
Q2 		$1.1M Buy
100,843
+2,363
+2% +$24.5K 0.27% 111
2022
Q1 		$1.11M Sell
98,480
-27,596
-22% -$363K 0.23% 127
2021
Q4 		$1.98M Sell
126,076
-69,950
-36% -$1.22M 0.41% 60
2021
Q3 		$3.36M Sell
196,026
-2,786
-1% -$48.8K 0.73% 19
2021
Q2 		$4.28M Buy
198,812
+19,123
+11% +$342K 0.77% 12
2021
Q1 		$2.7M Buy
179,689
+13,171
+8% +$213K 0.49% 51
2020
Q4 		$2.19M Buy
166,518
+8,514
+5% +$102K 0.47% 50
2020
Q3 		$1.53M Buy
158,004
+2,443
+2% +$26.1K 0.4% 62
2020
Q2 		$1.78M Buy
155,561
+10,135
+7% +$115K 0.45% 41
2020
Q1 		$1.51M Hold
145,426
– – 0.46% 43
2019
Q4 		$2.39M Buy
145,426
+97,219
+202% +$1.47M 0.45% 39
2019
Q3 		$640K Buy
48,207
+27,854
+137% +$388K 0.14% 242
2019
Q2 		$287K Sell
20,353
-34,980
-63% -$557K 0.06% 361
2019
Q1 		$1.02M Sell
55,333
-12,910
-19% -$294K 0.22% 151
2018
Q4 		$1.78M Sell
68,243
-15,600
-19% -$367K 0.42% 57
2018
Q3 		$1.92M Buy
83,843
+19,900
+31% +$406K 0.38% 69
2018
Q2 		$1.22M Buy
+63,943
New +$1.07M 0.25% 140
2017
Q1 		– Sell
-58,705
Closed -$936K – 544
2016
Q4 		$936K Sell
58,705
-700
-1% -$11.3K 0.23% 169
2016
Q3 		$988K Buy
+59,405
New +$800K 0.25% 152
2014
Q2 		– Sell
-71
Closed -$1K – 674
2014
Q1 		$1K Sell
71
-139
-66% -$1.98K ﹤0.01% 547
2013
Q4 		$2K Buy
210
+114
+119% +$1.15K ﹤0.01% 468
2013
Q3 		$1K Buy
+96
New +$1.03K ﹤0.01% 542

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Globeflex Capital's VNDA Position: Q4 2023 in Review

Globeflex Capital sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 96,331 shares — an estimated $416K sold.

Globeflex Capital first reported a position in VNDA in Q3 2013 and held it in 27 quarters. The position peaked at $4.28M in Q2 2021. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.

  • Globeflex Capital reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Globeflex Capital sold 96,331 Vanda Pharmaceuticals shares in Q4 2023, an estimated $416K.
  • Globeflex Capital first reported a position in Vanda Pharmaceuticals in Q3 2013 and held it in 27 quarters.
  • Globeflex Capital's Vanda Pharmaceuticals position peaked at $4.28M in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.

Based on Globeflex Capital's 13F filing for Q4 2023, filed 13 Feb 2024.